Evidence map›Paper›PMID 21766901›Full record

ArticleThe patient2011

Eliciting preferences for reimbursed drugs selection criteria in Côte d'Ivoire.

Vakaramoko Diaby, Henri Dié Kakou, Jean Lachaine

Erratum issuedAbstract readValidation Study
PubMed Publisher
In one paragraph

Article in The patient, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Attributes Development for Pharmaceutical Subsidization: A Qualitative Study.Iranian journal of pharmaceutical research : IJPR · 2020
    Article
  3. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Vakaramoko DiabyEconomic Evaluation Methods and Pharmacoeconomics, Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. vakaramoko.diaby@umontreal.ca
Henri Dié Kakou
Jean Lachaine
Université de Montréal · CASociété de Développement des Forêts · CI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCôte d'Ivoire, a West African country, has decided to set up a formulary as part of its universal health insurance (UHI) program. One of its goals will be to facilitate access to safe and efficacious drugs. To guarantee transparency throughout the formulary listing process, it is important to select and value relevant decision criteria for that purpose.

objectiveTo investigate the preferences of healthcare professionals (physicians) when selecting reimbursable drugs and to analyze trade-offs between criteria for formulary listing in Côte d'Ivoire.

methodsChoice sets based on four attributes (cost effectiveness of treatments, severity of the disease for which the treatments are indicated, age of the population affected by diseases considered, and social class affected by diseases considered [poor, rich]) were presented in a self-completion questionnaire.

resultsAnalysis of questionnaire responses showed that 'cost effectiveness', 'severity of disease', and 'social class' were significant attributes in responder's preferences for reimbursable drugs. More specifically, respondents' choices were more sensitive to drugs that are very cost effective, that target very severe disease, and that target diseases in poor people.

conclusionThis explorative study enabled us to elicit the preferences of a sample of healthcare professionals (physicians) for reimbursed drug selection criteria in Côte d'Ivoire using the discrete-choice experiment method. Further work is required to achieve the ultimate objective of developing a formulary for Côte d'Ivoire.

Indexed as

Attitude of Health PersonnelInsurance, Health, ReimbursementAdultCost-Benefit AnalysisCote d'IvoireDecision MakingFemaleHumansLogistic ModelsMaleMiddle AgedNational Health ProgramsPhysiciansPrescription DrugsSeverity of Illness IndexSocial ClassPrescription Drugs

Identifiers

PMID21766901
OpenAlexW2079103070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.